KV Pharmaceutical has signed an agreement with Gedeon Richter, USA for licensing rights to some of KV’ technologies and products in Women’s Health.
Under this agreement, Gedeon Richter got the rights to manufacture and distribute certain KV’ proprietary technologies and products in its territories, including the European Union.
The agreement also provides for the development of additional products in the future. KV retains the rights to the products and technology in the US.
Erik Bogsch, CEO, Gedeon Richter, said: “We consider this agreement as an important step towards our strategy acquiring projects or products with high added value nature, as it allows us to enhance our existing female healthcare portfolio, not only in our traditional markets, but in all the EU member states. Present in-licensed products, as well as Richter’s future proprietary development products will be produced at Richter’s facilities based on KV’s excellent technology platform.”